Abstract The relative importance of vessel wall tissue factor (TF) in initiating thrombogenesis is not well defined. In contrast, vessel wall collagens have been well documented as potent inducers of thrombus formation. We compared the potency of a human TF/phospholipid surface with that of a surface consisting of human type III collagen fibrils in triggering thrombus formation in native human blood at venous and arterial blood flow conditions. A commercial preparation, Thromborel S, was used as a source of human TF. Biochemical characterization of this preparation revealed small amounts of FVII, FIX, and FX proteins. Coagulant activity of these proteins was associated with the FVII protein only, although it was a very low activity. Studies with anti-TF antibodies in a one-stage clotting assay showed that the procoagulant activity of Thromborel was mainly a result of TF. The molar ratio of TF to phospholipid was 1:2 x 10 7 . Thrombus formation in flowing nonanticoagulated human blood drawn directly from an antecubital vein was triggered by either Thromborel S or collagen fibrils coated on Thermanox coverslips in a parallel-plate perfusion chamber device. A 1:50 Thromborel S dilution gave maximal fibrin T issue factor (TF) initiates coagulation through its interaction with the plasma coagulation protein FVTI/FVIIa. 12 Activated FVII (FVIIa) bound to TF activates the coagulation proteins FX and FIX, 34 which ultimately results in thrombin generation, fibrin formation, and platelet activation and aggregation.
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The wall shear rate has a profound impact on TF/ FVIIa-dependent FX activation, 5 -7 as well as on fibrin deposition and platelet thrombus formation. 815 The significance of TF for fibrin deposition and thrombus formation on subendothelium, 7 -13 ' 16 stimulated endothelial cells, 1718 and the extracellular matrix of stimulated endothelium 15 has been investigated in nonanticoagulated human blood by various perfusion chamber devices. These experiments have revealed a significant decrease in fibrin deposition with increasing shear and a concomitant enhancement of platelet thrombus formation. Immobilized purified TF reconstituted in phospholipid vesicles and TF expressed on fibroblasts have also been exposed to purified FVII and FX in flowing deposition (90% surface coverage) at a wall shear rate of 100 s"'. However, pretreatment of the TF surface with a monoclonal anti-TF antibody reduced this fibrin deposition by 93% (P<.001). Thus, TF was essential for the procoagulant activity of the Thromborel S surface in this flow system also. At higher wall shear rates (650 and 2600 s" 1 ), less fibrin was deposited, but the platelet thrombus formation on the fibrin mesh increased dramatically. Platelet thrombus formation was elicited on top of the fibrin mesh; platelets adhered exclusively to the fibrin strands formed on the Thromborel S surface. However, while much less fibrin was deposited on the collagen (/ > <.001), the platelet-collagen adhesion was substantially higher than the platelet-fibrin adhesion on the Thromborel S surface (P<.001). Despite these differences, the platelet thrombus formation promoted by TF was comparable to that triggered by the collagen fibrils at intermediate and high arterial shear condi-buffer, 57 which resulted in increased FXa generation with increasing shear rate. However, none of these systems have so far allowed studies of TF/FVIIa-induced thrombus formation in native human blood without the presence of other surface components affecting the thrombus formation.
We addressed this issue by preparing a TF/phospholipid-rich surface on Thermanox coverslips, which were subsequently exposed to human native blood at venous and arterial blood flow conditions. For this purpose we chose Thromborel S (Thromborel) (Behringwerke AG), which consists of a lyophilized TF preparation from human placenta that has been relipidated in a surfactant. This preparation is formulated for use in the determination of the prothrombin time and the coagulation factors II, V, VII, and X in routine clotting assays. All batches of Thromborel are standardized against the international reference thromboplastin. 19 The Thromborel preparation adhered tightly to Thermanox plastic coverslips, which allowed us to study thrombus formation in flowing nonanticoagulated human blood at high arterial wall shear forces. It was also of interest to compare thrombus formation on this procoagulant TF/ phospholipid surface with that triggered by nonprocoagulant fibrillar type HI collagen, since collagen is considered to be the strongest vessel wall inducer of thrombus formation.
Methods Antibodies
Two different murine monoclonal antibodies (mAbs) directed against human TF were used. aTFmAb#4509 (American Diagnostica [AD], catalogue No. 4509) inhibits human TF activity by blocking the formation of the TF-FVII complex (product information, AD). aTFmAb#4503 (AD, catalogue No. 4503), which has negligible effect on the procoagulant activity and the TF-FVII binding, 22 was used as a control antibody.
Quantification of TF in Thromborel
The amount of TF in Thromborel preparations (Behringwerke AG) was measured by an ELISA (Imubind; AD), with a murine anti-human TF mAb as capture antibody. One vial of Thromborel was dispersed in 2 mL deionized water, incubated for 15 minutes at 37°C, and diluted with 10 mmol/L Tris-HCl, pH 7.2, containing 0.15 mol/L NaCl, 2% bovine serum albumin, and 0.1% Tween 20, and the assay was performed according to the instructions provided by the manufacturer.
Inhibition of TF Activity in Thromborel
Thromborel was diluted in 0.9% saline to give a baseline clotting time within the range of 30 to 35 seconds. This Thromborel dilution was preincubated at 37°C either with different concentrations of anti-TF antibody (0 to 1000 nmol/L) for 30 minutes or with 133 nmol/L anti-TF antibody for various periods of time ranging from 3 to 240 minutes. Pooled citrated human plasma (100 /iL, 37°C) was then added to 100 jtL of the Thromborel-antibody preincubation mixture. Then 100 fiL of prewarmed (37°C) 25 mmol/L CaCl 2 was added, and the clotting time was measured automatically in a standard one-stage clotting assay (Thrombotrack 4, Nycomed Pharma).
Quantification of FVII, FIX, and FX Protein in Thromborel
The Thromborel preparation was tested for the presence of FVII, FIX, and FX antigens (Ag) with appropriate ELISA kits (Asserachrom VILAg, IX:Ag, X:Ag; Diagnostica Stago). The assays were performed according to the instructions provided by the manufacturer. A normal plasma pool was used as reference to calculate the concentration of the proteins in Thromborel. The lower detection limits of the respective assays were 2.3 pmol/L for FVII, 1.1 pmol/L for FIX, and 0.2 pmol/L for FX.
Quantification of FVII, FIX, and FX Coagulant Activity in Thromborel
Coagulant activities of FVII, FIX, and FX associated with the Thromborel preparation were measured automatically in a one-stage clotting assay. Thromborel was diluted in 0.9% saline to give a baseline clotting time within the range of 30 to 35 seconds. This Thromborel dilution (100 /iL) was preincubated at 37°C, and human plasma (100 pL, 37°C) was added. 
Determination of Phospholipid Concentration in Thromborel
The phosphate concentration in Thromborel was measured by a colorimetric method (Randox Laboratories Ltd). The phospholipid content was calculated from the phosphate content with a conversion factor of 25."
Preparation of Thromborel Surfaces
One vial of Thromborel was dispersed in 2 mL distilled water, incubated for 15 minutes at 37°C, and diluted in coating buffer (0.1 mol/L sodium carbonate, pH 9.5). The Thromborel preparation was always freshly prepared, and dilutions of 1:25, 1:38, 1:50, 1:75, 1:100, 1:250, and 1:500 were coated on Thermanox plastic coverslips (Miles Laboratories). The coverslips were stored in 70% ethanol and rinsed in distilled water before they were incubated at 4°C for 17 hours in 2 mL of the respective Thromborel dilutions. The Thromborel-coated coverslips were rinsed six times with sterile phosphate-buffered saline (PBS) and stored in PBS for a maximum of 7 hours at 4°C before use in perfusion experiments.
The stability of the procoagulant activity of the Thromborel surface during storage was determined by depositing 300 /xL of recalcified citrated plasma (1:1 dilution with 25 mmol/L CaCl 2 ) on the coated coverslip. The time from the deposition of recalcified plasma to the formation of visible fibrin (clotting time) was monitored while the coverslips were gently rocked. The procoagulant activity of the Thromborel surface was not significantly different after 1, 1.5, and 7 hours of storage, showing clotting times of 65±5, 68±5, and 61 ±7 seconds, respectively (mean±SEM, n=6).
Preincubation of Thromborel Surface With Antibody
Thromborel-coated coverslips were preincubated with either aTFmAb#4509 or aTFmAb#4503 (each at 167 and 667 nmol/L) dissolved in buffer C (in mmol/L: NaCl 130, KC1 2, NaHCO 3 12, CaCl 2 2.5, and MgCl 2 0.9; pH 7.4) for 30 minutes at 37°C and subsequently used in perfusion experiments. Control Thromborel-coated coverslips were incubated in buffer C only.
Preparation of Collagen Surface
Type III collagen was purified from a pepsin extract of human placenta by selective salt precipitation. 24 The collagen concentration was estimated from the amino acid composition analyzed by a Biotronik LC 5000 amino acid analyzer after 24 hours of hydrolysis of a purified sample in 6 mol/L HC1 under vacuum. Characterization of this collagen preparation was previously published. 23 Collagen fibrils were made by dialysis at 4°C against 20 mmol/L Na 2 HPO 4 , pH 7.5, for 48 hours. 12 The quality of the fibrillar collagen preparation was ensured by platelet aggregation studies. Washed Thermanox plastic coverslips were spray-coated with 0.5 mg/mL of fibrillar collagen to a final density of about 20 fig/cm 2 with an airbrush at a nitrogen operating pressure of 1 atm. 12 The collagen-coated coverslips were kept at 21 C C for 16 hours before use in perfusion experiments.
Blood Donors and Blood Samples
Nonanticoagulated blood for ex vivo perfusion experiments was donated by healthy nonsmoking individuals who denied ingestion of aspirin or other nonsteroidal anti-inflammatory drugs for at least 10 days before the study.
Blood was sampled from an antecubital vein through a No. 19 Butterfly Infusion Set (Abbott Laboratories). The first 4 mL was collected into EDTA for measurements of platelet count and hematocrit (Auto Counter AC 920, Swelab Instruments). The next 4.5 mL was collected into 0.129 mol/L trisodium citrate for determination of plasma fibrinogen (Immuno AG), and the next 50 mL was used directly for an ex vivo perfusion experiment. Platelet counts, hematocrits, and plasma fibrinogen levels were within the normal ranges.
Blood from the same donor was used in perfusion experiments comparing thrombus formation on antibody-preincubated surfaces and corresponding control surfaces.
Ex Vivo Blood Perfusions, Fixation, and Embedding
Ex vivo perfusions 26 were performed at 37°C. Human nonanticoagulated blood was drawn directly from an antecubital vein over either a Thromborel-coated or a collagencoated Thermanox coverslip positioned in a parallel-plate perfusion chamber. 12 - 27 The blood flow rate was maintained at 10 mlVmin for 5 minutes by an occlusive roller pump (model M312, Gilson) placed distal to the chamber. Perfusion chambers with different geometrical dimensions of the blood flow channel were used, such that a flow rate of 10 mL/min corresponded to shear rates at the surface of 100, 650, and 2600 s" 1 . 12 These wall shear rates are encountered in veins, medium-sized arteries, and moderately stenosed arteries, respectively. 27 Perfusions were performed with (1) coverslips incubated in seven different dilutions of Thromborel (1:25, 1:38, 1:50, 1:75, 1:100, 1:250, and 1:500) at a wall shear rate of 100 s" 1 ; (2) Thromborel-coated coverslips (1:50 dilution) incubated with aTFmAb#4509 or aTFmAb#4503 (each at 67 and 667 nmol/L) at a wall shear rate of 100 s" 1 ; (3) Thromborelcoated coverslips (1:50 dilution) at wall shear rates of 100, 650, and 2600 s" 1 ; and (4) collagen-coated coverslips at wall shear rates of 100, 650, and 2600 s"
1 . Blood perfusions were immediately followed by a 20-second perfusion (10 mL/min) with buffer C at 37°C and a 40 -second perfusion (10 mL/min) with a fixation solution at 21°C, consisting of 2.5% glutaraldehyde in 0.1 mol/L cacodylate, pH 7.4. The coverslips were immediately removed from the chamber and kept in a freshly prepared fixation solution for 1 hour. The specimens were stored in 0.1 mol/L cacodylate/7% sucrose at 4°C until embedded in epoxy resin.
light Microscopic Morphometry
Evaluations of thrombotic deposits were performed on epoxy resin-embedded semithin sections (1 jim) prepared perpendicular to the direction of the blood flow and 1 mm downstream from the inflow edge of the coverslip. 29 The sections were stained with toluidine blue and basic fuchsin. 30 The morphometry was performed blindly.
Percent surface coverage with fibrin (% fibrin deposition) and platelets (% platelet adhesion) was assessed by standard morphometry. 30 The evaluations were carried out at X1000 magnification with a Zeiss Standard 25 light microscope (Carl Zeiss).
Computer-assisted morphometry was used to quantify platelet thrombus area (jim 2 /jim sectional length). Platelet thrombus volume (jun 3 /^m 2 ) was derived from the sectional thrombus area as previously described. 29 The evaluations were performed by a Kontron Vidas image analyzing unit (Zeiss) at appropriate magnifications (x500 to X5000), depending on the size of the thrombi.
Representative light micrographs of sections prepared perpendicular to the direction of the blood flow were taken with a Zeiss Axiophot (Carl Zeiss).
Transmission Electron Microscopy
Transmission electron microscopy was performed on thrombotic deposits embedded in epoxy resin. Sections 50 nm thick were prepared on a LKB III microtome with glass knives. The sections were placed on Formvar/carbon-coated 75-mesh copper grids and stained for 2 minutes with a saturated uranyl acetate solution in 50% ethanol and 2 minutes in 0.2% lead citrate solution in 0.1 mol/L NaOH. The sections were examined with a JEOL 1200EX transmission electron microscope and an accelerating voltage of 80 kV.
Scanning Electron Microscopy
Scanning electron microscopy was performed on Thromborel-coated Thermanox coverslips after blood perfusion at 100 s" mol/L cacodylate buffer (pH 7.4), dehydrated in graded ethanols, and critical-point-dried (Polaron E 3100 Critical Point Drier, Polaron Equipment Ltd) with carbon dioxide used as the transitional fluid. The coverslip was then adhered to carbon stubs and coated with a layer of gold/palladium alloy 300 A thick in a Polaron E 5100 Sputter Coater. The specimens were examined and photographed with a Phillips SEM 515 microscope with a conventional secondary detector at magnifications of x 100 and x 10 000 on areas located 1 to 3 mm downstream from the inflow edge of the coverslip.
Statistical Analysis
The results are expressed as mean±SEM. The significance for paired and unpaired data was calculated with Student's t test as appropriate. Values of P<.05 were considered significant. Two-tailed probabilities were used throughout the study.
Results

Biochemical Characterization of Thromborel Amounts of TF, FVII, FIX, FX, and Phospholipids in Thromborel
The amounts of TF, FVII, FIX, and FX in Thromborel were measured with appropriate ELISA kits (Table). The amount of TF was determined at a high dilution (1:640) of Thromborel.
The phospholipid content of Thromborel was found to be 95 ^.molAial, giving a molar ratio of TF to phospholipid of l:2xlO 7 .
TF Coagulant Activity in Thromborel
The TF procoagulant activity of Thromborel in a one-stage clotting assay was inhibited by mAbs directed against human TF. aTFmAb#4509 (67 nmol/L) preincubated with Thromborel for 30 minutes increased the clotting time from 34 to 208 seconds. However, aTFmAb#4503 had only a small effect, increasing the clotting time from 33 to 41 seconds at similar experimental conditions. Increasing the concentration of antibodies or the preincubation time did not affect the clotting time.
Coagulant Activity of FVII, FIX, and FX in Thromborel
Coagulant activity of FVII, FIX, and FX in Thromborel was measured in a one-stage clotting assay using plasma deficient in FVII, FIX, or FX (Table) . The clotting time increased more than fourfold with FVTIdeficient plasma, showing that the coagulant activity of FVII in Thromborel preparation is minor. FIX-deficient plasma had no effect on the clotting time. FX-deficient plasma increased the clotting time to more than 400 seconds, indicating that no detectable FX coagulant activity is present in the Thromborel preparation.
Ex Vivo Perfusion Experiments Surface Density of TF Coating and Fibrin Deposition
Fibrin deposition in nonanticoagulated blood at a wall shear rate of 100 s" 1 on coverslips incubated in different dilutions of Thromborel are shown in Fig 1. Percent surface coverage with fibrin was dependent on the Thromborel dilution, varying from 25±17% (n=6) at the lowest dilution (1:25) to 90 ±6% at the 1:50 dilution (n=6). The 1:50 dilution gave maximal fibrin deposition with minimal variations, and this dilution was used in the subsequent experiments.
The fibrin mesh after 5 minutes of perfusion at a wall shear rate of 100 s" 1 had a thickness varying from about 2 fim to more than 5 fitn, showing a pearl configuration in semithin cross sections (Fig 2A) . Few platelets were deposited, and they were always associated with fibrin. The percentage of the fibrin surface covered by platelets varied from 1% to 7% irrespective of the Thromborel dilution (nonsignificant). The average thrombus volumes at the different Thromborel dilutions were <0.8 /xm 3 //u.m 2 and were independent of the Thromborel dilution.
Thromborel and Anti-TF Antibodies
Preincubation of Thromborel-coated coverslips with 167 and 667 nmol/L aTFmAb#4509 reduced the fibrin deposition at a wall shear rate of 100 s" 1 from 96% to 25% (74% reduction) and from 91% to 6% (93% reduction), respectively (Fig 3) . Preincubation with the control antibody, aTFmAb#4503, resulted in a reduction (not statistically significant) of fibrin deposition from 93% to 83% at 67 nmol/L and from 87% to 64% at 667 nmol/L. Platelet deposition occurred exclusively on the fibrin mesh. The platelet-fibrin adhesion and platelet thrombus volume were less than 3% and 1.4 ^m 3 /
FIG 2. Ught micrographs of representative blood-Thromborel
Interactions after 5 minutes of perfusion with nonanticoagulated human blood at wall shear rates of (A) 100 s" 1 , (B) 650 s~', and (C) 2600 s" 1 . Note that platelet thrombi (large arrow) are deposited exclusively on the top of the fibrin mesh (small arrow). Sections were prepared perpendicular to the direction of the blood flow 1 mm downstream from the upstream edge of the coverslip. Magnification X1200. Bar represents 10 /im. fim 2 , respectively, and were not significantly affected by either aTFmAb#4509 or aTFmAb#4503.
Thromborel-and Collagen-Induced Thrombogenesis: Effect of Shear Rate
Fibrin deposition on Thromborel was negatively associated with increasing wall shear rate, decreasing on Thromborel and collagen surfaces. Note that platelets adhere only to fibrin on the Thromborel surface. The surfaces were exposed to flowing nonanticoagulated blood for 5 minutes at wall shear rates of 100, 650, and 2600 s"'. Results are given as mean±SEM. For Thromborel: n=6 for 100, 650, and 2600 s" 1 . For collagen: n»6 for 100 and 650 s" 1 and n=12 for 2600 s" 1 . Student's f test for unpaired data. *P<.05, **P<.01, and ***P<.001, Thromborel surface compared with collagen surface. from 90% at 100 s" 1 to 66% at 2600 s" 1 (P<.05) ( Fig  4A) . Fig 2 shows representative light micrographs of blood-Thromborel interactions at wall shear rates of (A) 100, (B) 650, and (C) 2600 s" 1 . The fibrin mesh at 2600 s~' appeared morphologically less densely packed with thinner fibrils than at 100 s~'. In contrast, plateletfibrin adhesion and platelet thrombus volume increased with increasing shear (Fig 4B and 4C) . The percent surface coverage with platelets on the fibrin mesh increased from 6% at 100 s" 1 to 18% at 2600 s" 1 (P<.05). The platelets were not adherent to the Thromborel surface but rather exclusively to fibrin strands deposited on the Thromborel coating. The thrombus volume increased from 0.6 nm 3 /fim 2 at 100 s~' to 24 at 2600 s' 1 (P<.001). Thrombus formation on the Thromborel surface was compared with thrombus formation triggered by collagen type III fibrils at wall shear rates of 100, 650, and 2600 s" 1 (Fig 4) . Surface coverage with fibrin was significantly lower on collagen than on the Thromborel surface at all three shear rates, 22% versus 90% at 100 s~\ 5% versus 88% at 650 s~\ and 3% versus 66% at 2600 s" 1 (P<.001) (Fig 4A) . In contrast, platelet-fibrin adhesion on the Thromborel surface was much lower than the platelet-collagen adhesion; 6% versus 28% at 100s-1 (P<.00l), 7% versus 28% at 650 s" 1 (P<.01), and 18% versus 66% at 2600 s" 1 (F<.001) (Fig 4B) . However, the platelet thrombus volumes induced by Thromborel and collagen were not significantly different at arterial shear rates (Fig 4C) .
Morphology: TF-Induced Thrombus Formation
Light and transmission electron micrographs from sections (Thromborel surface) prepared perpendicular to the direction of the blood flow showed that fibrin deposited on the Thromborel surface and that platelets deposited on top of the fibrin mesh (Figs 2 and 5 ). Transmission and scanning electron micrographs (Figs 5 and 6, respectively) showed that the fibrin strands were oriented primarily in the direction of blood flow. Red blood cells were frequently entrapped in the fibrin meshwork, as shown in Fig 6. Transmission electron micrographs from sections prepared parallel to the direction of blood flow showed the morphological ap- pearance of longitudinal fibrin strands, with the typical striated pattern of 23-nm periodicity 31 (Fig 7) .
Discussion
The biological function of TF in health and disease has gained considerable interest during the past decade. 12 A role for TF/FVIIa-induced coagulation in thrombotic events associated with disseminated intravascular coagulation, 32 arterial plaque rupture, 33 -34 and early reocclusion following percutaneous transluminal coronary angioplasty procedures 35 has been implicated for some time. However, the relative importance of TF in these processes has not been well established, particularly with respect to the blood flow.
In the present investigation we characterized the role of immobilized TF embedded in a phospholipid-rich surface in thrombus formation at blood flow conditions mimicking those in veins, average-sized arteries, and moderately stenosed arteries. We found that TF/FVIIainduced coagulation elicited profound platelet thrombus formation at these blood flow conditions, to an extent similar to purified human type III collagen fibrils. However, the sequence of events during thrombus formation was different. The TF/phospholipid-rich surface triggered pronounced fibrin deposition that subsequently served as a carpet for platelet adhesion and platelet-platelet interactions. In contrast, fibrin deposition on the collagen surface was sparse, and platelets adhered directly to the collagen fibrils where the platelet-platelet interaction subsequently took place. Thus, the fibrin mesh deposited on the TF/phospholipid surface triggered platelet thrombus formation as efficiently as the collagen fibrils at arterial shear conditions, implying that TF in the vessel wall is at least as thrombogenic as collagen type III fibrils.
The blood flow conditions had a large impact on both fibrin deposition and platelet-thrombus formation on the TF/phospholipid surface. The deposition of fibrin was substantially higher at arterial shear conditions than on TF-containing arterial subendothelium, 13 stimulated endothelium, 18 -36 or the extracellular matrix of stimulated endothelium. 15 It is possible that the phospholipid-rich TF surface more efficiently promoted the formation of the prothrombinase and/or thrombinase complexes and thus the fibrin deposition than the biologically derived surfaces. However, the volume of the platelet-rich thrombi, which increased in concert with the wall shear rate, was within the range of those that form on collagen, subendothelium, 13 and matrix. 15 Thus, the shear-dependent platelet thrombus volume formation on the fibrin mesh was much like that observed on TF-containing subendothelium and extracellular matrix of stimulated endothelium, despite the substantially higher platelet adhesion to fibrin than to the collagen fibrils. However, the biologically derived surfaces probably contain other surface components besides TF that may modulate thrombus formation. The Thromborel preparation used in these experiments does not consist of TF and phospholipids alone; rather, small amounts of FVII, FIX, and FX could also be detected. However, coagulant activity of these proteins, although low, was associated with FVII only. Unfortunately, the clotting assay is not optimal for measuring the FIX coagulant activity in Thromborel. mAbs against FIX that block the coagulant activity completely are not available; therefore, it is difficult to assess the FIX activity of the Thromborel preparation in other systems as well. Experiments with the anti-TF antibody aTFmAb#4509, which blocks the binding of FVII to TF, indicate that the procoagulant activity of the Thromborel surface was almost entirely due to TF. The coagulation studies and the blood perfusion experiments were consistent in this regard. These observations support the use of Thromborel as a source of TF in perfusion experiments, particularly for studies of the role of the extrinsic pathway of coagulation in thrombus formation.
It is well known that TF preparations have maximal effect on the clotting time at a definite dilution. However, this concentration may not be the same in a test tube as when coated on a surface and exposed to flowing blood. Experiments were therefore carried out to establish the optimal Thromborel dilution for coating. It appeared that a 1:50 dilution gave maximal and highly reproducible fibrin deposition at a wall shear rate of 100 s" 1 . The enormous excess of phospholipids in the Thromborel preparation may have a shielding effect on the presentation of biologically active TF at lower dilutions, a phenomenon also seen in the TF ELISA.
The reproducibility of the Thromborel surface in eliciting thrombus formation in the parallel-plate perfusion device was as good as that previously observed with the well-characterized preparation of type III collagen fibrils, 12 stimulated endothelium, 18 -36 and the extracellular matrix of stimulated endothelium. 15 Another reason to make use of and to characterize the Thromborel surface in the perfusion device was to replace the TF-containing endothelial and matrix surface with a purified TF/phospholipid surface, since the latter surfaces are rather time-consuming to prepare and may present considerable variation in the TF content. 37 Another advantage of the Thromborel surface over the cell-derived surfaces is the lack of other cellular prothrombotic and antithrombotic properties that may modulate the TF-dependent thrombus formation.
It appears that Thromborel offers a relatively wellcharacterized TF/phospholipid surface, which allows reproducible studies of TF-dependent thrombus formation. It is also apparent that immobilized TF is as thrombogenic as immobilized collagen fibrils in the perfusion device at arterial shear rates. The observation of a significant thrombogenic stimulus of TF at intermediate and high arterial shear conditions may also have implications for the treatment of arterial thrombotic disorders.
